COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk NOVOb.CO CEO Mike Doustdar on Thursday told analysts in a call that people taking a compounded copy of the drugmaker's Wegovy pill priced at $49 will be wasting their money as the compound will not be absorbed in their body.
(Reporting by Maggie Fick and Louise Rasmussen, editing by Terje Solsvik)
((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))